Dublin, Ireland, August 17th 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr. Mario Rocci to the position of President, ICON Development Solutions.
Dr. Rocci joined ICON through the acquisition of Prevalere Life Sciences in 2008, where he served as Chief Executive Officer, and has led ICON’s global bioanalytical business since that time. He has over 29 years of experience in the pharmaceutical industry and prior to joining Prevalere in 1988, held the position of Head of the Laboratory of Investigative Medicine and Research Associate Professor of Medicine at Thomas Jefferson University. Dr. Rocci was also Clinical Associate Professor of Pharmacy Practice at the Philadelphia College of Pharmacy and Science. He has authored over 125 scientific publications and has extensive expertise in the pharmaceutical sciences, clinical pharmacology and the regulatory requirements of the FDA. Dr. Rocci holds a Ph.D. in Pharmaceutics and a B.S. in Pharmacy from the State University of New York at Buffalo.
Dr. Rocci succeeds Dr. Thomas Frey, who has been with ICON for over 11 years and who will retire in 2012. In the meantime, Dr. Frey will lead one of the company’s significant change management projects.
Commenting on the appointment, Mr. Peter Gray, CEO ICON plc said, “Mario has done an excellent job in building and shaping our bioanalytical capabilities and under his tenure we have been successful in forming strategic partnerships in this area with some large pharma clients. Building on Thomas’ work, Mario’s deep scientific knowledge and industry experience will be invaluable as we look to strengthen our early phase business and help clients through the dynamic changes impacting the drug development process.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,800 employees, operating from 77 locations in 39 countries.
Further information is available at www.iconplc.com
Contacts
Yasamin Omoomian
Weber Shandwick
+44 (0)20 7067 0594
